

Table 10. Percentages of Tuberculosis Cases, by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2016

Year	Initial drug regimen ^{1,2}			Directly observed therapy ³		Therapy ≤1 year indicated ⁴	
	IR	IRZ	IRZE	DOT only	Both DOT and self-administered	COT ≤1 Year	COT ever
1993	(13.0)	(31.2)	(40.3)	(21.7)	(14.4)	(63.4)	(86.0)
1994	(7.0)	(23.3)	(55.7)	(28.1)	(20.5)	(68.6)	(86.8)
1995	(5.2)	(20.3)	(62.7)	(37.3)	(21.5)	(74.1)	(89.2)
1996	(4.2)	(17.5)	(67.3)	(42.5)	(22.4)	(76.8)	(90.2)
1997	(3.2)	(15.1)	(71.9)	(47.0)	(23.8)	(78.7)	(91.0)
1998	(2.6)	(12.9)	(74.3)	(47.7)	(26.6)	(81.2)	(92.2)
1999	(2.2)	(11.2)	(76.9)	(49.4)	(27.6)	(81.4)	(92.2)
2000	(2.0)	(10.4)	(78.5)	(52.5)	(25.8)	(82.2)	(92.5)
2001	(1.7)	(9.6)	(79.8)	(53.6)	(27.5)	(82.5)	(92.7)
2002	(1.8)	(8.9)	(80.3)	(55.4)	(27.8)	(83.0)	(92.5)
2003	(1.4)	(8.1)	(81.3)	(56.5)	(28.5)	(83.6)	(92.8)
2004	(1.5)	(6.4)	(82.4)	(58.9)	(27.7)	(84.3)	(92.6)
2005	(1.3)	(5.5)	(83.7)	(57.9)	(29.6)	(84.0)	(92.5)
2006	(1.2)	(4.8)	(83.3)	(57.5)	(30.4)	(84.8)	(93.2)
2007	(1.1)	(4.6)	(83.8)	(56.3)	(32.9)	(85.6)	(93.9)
2008	(1.0)	(3.5)	(84.2)	(56.4)	(33.5)	(86.1)	(93.3)
2009	(0.9)	(3.1)	(84.3)	(59.6)	(30.3)	(88.8)	(95.6)
2010	(0.8)	(2.8)	(84.5)	(59.3)	(31.1)	(89.7)	(96.1)
2011 ⁵	(0.7)	(2.6)	(85.2)	(62.2)	(29.2)	(89.7)	(96.4)
2012 ⁵	(0.6)	(2.0)	(85.4)	(61.8)	(29.1)	(90.1)	(96.4)
2013 ⁵	(0.5)	(2.3)	(84.5)	(63.2)	(28.8)	(89.8)	(96.2)
2014 ⁵	(0.3)	(2.2)	(85.3)	(63.9)	(29.0)	(90.1)	(96.6)
2015 ⁵	(0.4)	(2.0)	(85.2)	—	—	—	—
2016 ⁵	(0.4)	(1.7)	(84.8)	—	—	—	—

¹Includes persons alive at diagnosis.

²I, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol. Excludes cases with no information on initial drug regimen. In 2016, 0.8% received no initial drug therapy, 0.1% were started on one drug, and 12.2% had an initial drug regimen other than IR, IRZ, or IRZE.

³Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.

⁴Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, and who did not die within one year of initiating therapy. Persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment were excluded.

⁵Beginning in 2011, those who moved out of country during treatment are excluded from the denominator of those eligible for COT.

Note: Data as of June 21, 2017.

See Technical Notes for details and for description of COT calculation.

See Surveillance Slides #30 and #31.